Sale of 185 shares at $18.88 per share.
Reporting Person Friedl-Naderer Johanna · Officer Title Chief Commercial Officer · Transaction Code S
Traded Sep 8, 2026 · Disclosed Sep 8, 2026
Source: SEC Form 4 · 0001915598-26-000005 · filed 2026-09-08 · View filing →
Composed from the Form 4 as filed with the SEC. Share counts, prices and dates are the filing's own; the disclosure lag is counted in business days from the transaction date to the filing date. What is a Form 4?
Cite this card
Desq Long. "Dyne Therapeutics, Inc. (DYN)." Disclosed 2026-09-08. https://desqlong.com/cards/0001915598-26-000005-2 (retrieved 2026-09-26).